Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion
Enrolling by invitationOBSERVATIONAL
Enrollment
3,000
Participants
Timeline
Start Date
June 27, 2024
Primary Completion Date
June 27, 2030
Study Completion Date
June 30, 2031
Conditions
Coronary Artery Disease(CAD)
Trial Locations (1)
44033
Ulsan University Hospital, Ulsan
All Listed Sponsors
lead
Genoss Co., Ltd.
INDUSTRY
NCT07158307 - Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion | Biotech Hunter | Biotech Hunter